MindImmune Therapeutics’ Issuance and Sale of $12.4 Million Series A Convertible Preferred Stock

Locke Lord advised MindImmune Therapeutics, Inc. on the deal.MindImmune Therapeutics Inc., a drug discovery company pioneering a new approach to treat Alzheimer’s disease and other neuro-degenerative…

This content is for Standard 1 Year members only.
Login Join Now
Martina Bellini

Author: Martina Bellini

This content is for Standard 1 Year members only.
Login Join Now